Please assess the completion status of the following clinical trial:

Trial Title: Determining Metabolic Effects of Valproate and Antipsychotic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria for schizophrenia, any type, treated with the same antipsychotic for at least 6 months~* No antipsychotic medication dose changes for 1 month, and no other medication changes for 1 month prior to study entry~Exclusion Criteria:~* Meets DSM-IV criteria for substance abuse within 3 months of study entry~* Involuntary legal status (as per Missouri law)~* Any serious medical disorder that may confound the assessment of relevant biologic measures or diagnosis, including: significant organ system dysfunction, metabolic diseases, type 1 or 2 diabetes mellitus, pregnancy, endocrine disease, coagulopathy, anemia, or acute infection~* Currently taking more than one antipsychotic medication~* Currently taking prescription medications (except certain psychotropic medications as discussed below), including oral contraceptive pills, any glucose lowering agent, lipid lowering agent, exogenous testosterone, recombinant human growth hormone, or any other endocrine agent that might confound substrate metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 50% of participants will receive placebo
- Experimental (Type: EXPERIMENTAL): 50% of participants will receive Depakote ER

Based on this trial design, predict the completion outcome and termination type (if applicable).